公开(公告)号：EP4279128A2

公开(公告)日：2023-11-22

申请号：EP23196718.3

申请日：2015-12-29

申请人： Mogam Institute for Biomedical Research

发明人： KIM, Dong-Sik ,  LEE, Mi Jung ,  PARK, Jae Chan ,  LEE, Sumin ,  KWAK, Heechun ,  HWANG, SungHo ,  LIM, Hyung-Kwon ,  KIM, Kisu ,  PARK, Young Seoub ,  JEONG, Junhong ,  CHO, Ki Joon

IPC分类号： A61P7/04

摘要： The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.

公开(公告)号：EP4279128A3

公开(公告)日：2024-02-28

申请号：EP23196718.3

申请日：2015-12-29

申请人： Mogam Institute for Biomedical Research

发明人： KIM, Dong-Sik ,  LEE, Mi Jung ,  PARK, Jae Chan ,  LEE, Sumin ,  KWAK, Heechun ,  HWANG, SungHo ,  LIM, Hyung-Kwon ,  KIM, Kisu ,  PARK, Young Seoub ,  JEONG, Junhong ,  CHO, Ki Joon

IPC分类号： C07K16/38 ,  C12N15/63 ,  A61K39/395 ,  A61P7/04 ,  A61P7/00

摘要： The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.

公开(公告)号：EP3262075A1

公开(公告)日：2018-01-03

申请号：EP15883495.2

申请日：2015-12-29

申请人： Mogam Institute For Biomedical Research

发明人： KIM, Dong-Sik ,  LEE, Mi Jung ,  PARK, Jae Chan ,  LEE, Sumin ,  KWAK, Heechun ,  HWANG, SungHo ,  LIM, Hyung-Kwon ,  KIM, Kisu ,  PARK, Young Seoub ,  JEONG, Junhong ,  CHO, Ki Joon

IPC分类号： C07K16/36 ,  C12N15/63 ,  A61K39/395 ,  A61P7/04

CPC分类号： C07K16/38 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/72 ,  C07K2317/92

摘要： The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.